Rosma Napitupulu, director of UKI Krankenhaus; Anyway Dr. H.Bucholt, director of DAAD Indonesia of our unterstutzt hat. R Soeparwata – DIGM, RSCM-FK UI) 3. Early detection of breast cancer (Enos H. Siburian, dr., SpB, SpBOnk. – RS UKI) 4. Antioxidant and immunomodulation capacity of some common food products representing functional foods (Prof . R Soeparwata – DIGM, RSCM-FK UI) 3. Early detection of breast cancer (Enos H. Siburian, dr., SpB, SpBOnk. – RS UKI) 4. Antioxidant and immunomodulation capacity of some common food products representing functional foods ( Prof. Dr.
Ir. Fransiska Rungkat-Zakaria, IPB Lunch Symposium—Cervical Cancer (Glaxo-Smith & Kline Symposium II: The Future of Medical Science and Health Services: Moderator: Sahala Panggabean, dr., SpPD, KGH Dr.med. Buchholt (DAAD) Seminar I : Women's role in health improvement Moderator: Bernadetha, Nadeak, dr., MPd.Ked.: 1. Virginity and health of reproductive organs (Women's struggle to preserve their health and moral values in the patriarchal society): Dr. Tommy Tiluata, Sp. .BTKV 1. Techniques and safety of facelift surgery (dr. Ago Harlim, MARS, SpKK.) 2. Management of acne (dr. Vitalis Pribadi, SpKK, MKes.-FK UKI) Seminar III: New treatment of breast cancer (EISAI) Coffee break .
Martina Wiwie) 2. Menopause-related diseases (Dr. Jan Purba, PhD) 3. Peritoneal (dry type) and small intestinal tuberculosis in female patients with psychiatric disorders (Maria Goretti Amatembun, Dr., SpPD) 4. Metabolic complications in women living with HIV/AIDS (Erika Ferrari Rafael da Silva MD, PhD). Rondang Soegianto-Siagian, PhD 1. Epigenetic control of maternal health (Dr. Trina Tallei-Unsrat) 2. The role of USG in obstetric care to reduce maternal and perinatal mortality rates (Prof. Dr. Retno Wahyuningsih , SpParKlin.-FK UKI) 4. Current management therapy in breast cancer: the role of PET CT and radiotherapy with RAPID ARC (Dr. Fielda Djuita, SpR and Dr. Basuki Hidayat, SpKN) Reproductive health and family planning: National Population and Family Planning Board (BKKBN) .
Moderator: Januar Simatupang, SpOG 1. Family Planning Grand Design (Dr. Poppy Irawati, MPH) 2. Complications during childbirth based on IDHS 2007 (Dr. Nia Reviani, MAPS).
Term of Reference DIGM-GIMA
Board of Committee (1997-2002)
Regional Coordinators
Board of Committee (2002-October 2006)
During this era, DIGM also took an active role in many health aspects of the country. Abraham Simatupang went on a 2-week mission to Banda Aceh on a humanitarian relief operation for tsunami victims who were estranged in remote areas. They moved to their immediate families after receiving emergency aid from the Red Cross and other relief NGOs.
Simatupang and the team made home visits and gave them the medical and psychological aids they needed. Simatupang was in Sigli, he also sent a child who had a hernia to the German Military Mobile Hospital in Banda Aceh and the child was successfully operated by the team doctors of the German Military Mobile Hospital. When Dr.Heston Napitulu from Universitas Kristen Indonesia asked DIGM Indonesia to help him with an opportunity to take specialization in cardiac surgery, we referred the intention to DIGM German Chapter and we received a positive response from Prof.
Board of Committee
October 2006-September 2008)
Strategic Plan Vision
Mission Statements
Strategies
Publications: 5 proceedings of symposia and seminars, 1 scientific journal (DIGM Medical Journal), which is published twice a year (January-June & July-December), and since February 2011, DIGM Medical Journal has a strategic partnership with the Medical Journal of Indonesia - Medicinska faculty – University of Indonesia.
Further planned Activities
List of sponsors and contributors
Portraits of Breast Cancer Survivor Whom With Surrender But Endeavor
Abstract
Sex-linked Pharmacodynamics-Pharmacokinetics differences of Drugs’ Effects
This was followed by the creation of guidelines and policies of the National Institutes of Health (NIH) in the USA for the inclusion of women in clinical trials.1 Biological differences between men and women can also determine the pharmacokinetic and pharmacodynamic effects of some drugs, as many studies have shown. It shows that despite the overall good results of aspirin compared to placebo, a total of 27% of the variation in non-fatal MI outcomes could be explained by considering the gender mix of the trials (p = 0.017). The answer to the question of why the pharmacokinetics of drugs might be different in women than in men is based on two pharmacokinetic indicators, i.e.
According to Soldin et al.5, there are at least three reasons for gender differences in the adverse effects that may arise from drugs taken by women, as suggested in Table 1 (see below). As can be seen in Table 1, many pharmacological factors intertwine with each other, which can present us with difficulties in determining which was the main factor that, in addition to their therapeutic effects, would cause side effects.
Pharmacokinetics factors in women
Some in-vitro findings, which are sometimes inconsistent with in-vivo results, have shown CYP1A2 to be responsible for the metabolism of drugs, including clozapine, olanzapine, theophylline and ondansetron. This isozyme is highly activated in smokers, so we can predict that the concentration of the above-mentioned drugs is higher in women than in men, while men are usually smokers. Another polymorphic isozyme called CYP2C9 is also responsible for the metabolism of various drugs such as phenytoin, some nonsteroidal anti-inflammatory drugs (NSAIDs, piroxicam, diclofenac, and ibuprofen) and sulfonylureas (glimepiride, glipizide, and glyburide).
Although this isozyme is polymorphic, there is no sex-specific difference in metabolic activity, except for phenytoin, as reported by Meyer et al.15 Carrasco-Portugal and Flores-Murrieta collected the differences of some important CYP isoenzymes, as shown in Table 2.4. In terms of excretion, the glomerular filtration rate (GFR) is lower in women than in men; moreover, after normalizing GFR for body size, a 10% difference is still seen. These characteristics lead to gender-related differences in pharmacokinetics, leading to reduced bioavailability and thus a different pharmacodynamic profile.
Due to changes in the PK profiles of drugs leading to a change in effects, we sometimes need to alternate dosages or take extra precautions due to the unwanted effects that may occur.
Herbal medicine and conventional medicine
Conclusion
Alpha 1-Acid Glycoprotein Microerogenicity: Variation During the Menstrual Cycle in Healthy Women and Profile in Women Receiving Estrogen-Progestogen Treatment.
INDOSTAFF Forum: Women in Education Women participation in all aspects of life is lower than men. They
Objectives
Frauen und Gesundheit: Auf dem Weg zu einem besseren Verständnis und einem besseren Umfeld für die Zukunft. Indonesische Deutsche Gesellschaft für Medizin.
Women & Health: Towards a better understanding and environment for the future
PROCEEDING SEMINAR
Penerbit
